EMEA-003317-PIP02-22 - paediatric investigation plan

varicella virus OKA strain (live, attenuated)
PIPHuman

Key facts

Active substance
varicella virus OKA strain (live, attenuated)
Therapeutic area
  • Infectious diseases
  • Vaccines
Decision number
P/0066/2023
PIP number
EMEA-003317-PIP02-22
Pharmaceutical form(s)
Powder and solvent for solution for injection
Condition(s) / indication(s)
Prevention of Varicella Zoster virus disease
Route(s) of administration
Parenteral use
Contact for public enquiries

GlaxoSmithKline Biologicals SA

E-mail: eu.paediatric-plans@gsk.com
Tel: +1 4388998201

Decision type
W: decision granting a waiver in all age groups for all conditions or indications
Decision date
Compliance check done
No

Decision

Share this page